These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33030135)

  • 1. Phenanthridine Sulfonamide Derivatives as Potential DPP-IV Inhibitors: Design, Synthesis and Biological Evaluation.
    Khalaf RA; Alqazaqi S; Aburezeq M; Sabbah D; Albadawi G; Sheikha GA
    Curr Comput Aided Drug Des; 2022; 18(1):9-25. PubMed ID: 33030135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, Biological Evaluation, and QPLD Studies of Piperazine Derivatives as Potential DPP-IV Inhibitors.
    Khalaf RA; Jarad HA; Al-Qirim T; Sabbah D
    Med Chem; 2021; 17(9):937-944. PubMed ID: 32940185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Piperazine sulfonamides as DPP-IV inhibitors: Synthesis, induced-fit docking and
    Khalaf RA; Alwarafi E; Sabbah D
    Acta Pharm; 2021 Dec; 71(4):631-643. PubMed ID: 36651550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DPP-IV Inhibitory Phenanthridines: Ligand, Structure-Based Design and Synthesis.
    Khalaf RA; Masalha D; Sabbah D
    Curr Comput Aided Drug Des; 2020; 16(3):295-307. PubMed ID: 30526469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, Structural Characterization and Docking Studies of Sulfamoyl- Phenyl Acid Esters as Dipeptidyl Peptidase-IV Inhibitors.
    Khalaf RA; Sabbah D; Al-Shalabi E; Al-Sheikh I; Albadawi G; Abu Sheikha G
    Curr Comput Aided Drug Des; 2018; 14(2):142-151. PubMed ID: 29521244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors.
    Patel BD; Bhadada SV; Ghate MD
    Bioorg Chem; 2017 Jun; 72():345-358. PubMed ID: 28302310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2
    Musoev A; Numonov S; You Z; Gao H
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31394858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational design and synthesis of new tetralin-sulfonamide derivatives as potent anti-diabetics and DPP-4 inhibitors: 2D & 3D QSAR, in vivo radiolabeling and bio distribution studies.
    Abd El-Karim SS; Anwar MM; Syam YM; Nael MA; Ali HF; Motaleb MA
    Bioorg Chem; 2018 Dec; 81():481-493. PubMed ID: 30243239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation.
    Meduru H; Wang YT; Tsai JJ; Chen YC
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27304951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory evaluation of
    Zabidi NA; Ishak NA; Hamid M; Ashari SE; Mohammad Latif MA
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):109-121. PubMed ID: 33249946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel N-substituted aminobenzamide scaffold derivatives targeting the dipeptidyl peptidase-IV enzyme.
    Al-Balas QA; Sowaileh MF; Hassan MA; Qandil AM; Alzoubi KH; Mhaidat NM; Almaaytah AM; Khabour OF
    Drug Des Devel Ther; 2014; 8():129-63. PubMed ID: 24470754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors.
    Li Q; Zhou M; Han L; Cao Q; Wang X; Zhao L; Zhou J; Zhang H
    Chem Biol Drug Des; 2015 Oct; 86(4):849-56. PubMed ID: 25787859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
    Li N; Wang LJ; Jiang B; Li XQ; Guo CL; Guo SJ; Shi DY
    Eur J Med Chem; 2018 May; 151():145-157. PubMed ID: 29609120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes.
    Singh AK; Jatwa R; Purohit A; Ram H
    J Asian Nat Prod Res; 2017 Oct; 19(10):1036-1045. PubMed ID: 28351157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Potential Dipeptidyl Peptidase (DPP)-IV Inhibitors among
    Yang Y; Shi CY; Xie J; Dai JH; He SL; Tian Y
    Molecules; 2020 Jan; 25(1):. PubMed ID: 31906524
    [No Abstract]   [Full Text] [Related]  

  • 16. Study on gluco-regulatory potential of glimepiride sulfonamide using in silico, in vitro and in vivo approaches.
    Parmar HS; Bhinchar MK; Bhatia M; Chordia N; Raval I; Chauhan DS; Manivannan E; Jatwa R; Kumar A
    Curr Pharm Des; 2014; 20(32):5212-7. PubMed ID: 24641189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated Protocol to Design Potential Inhibitors of Dipeptidyl Peptidase- 4 (DPP-4).
    Pantaleão SQ; Philot EA; de Oliveira Almeida M; Lima AN; de Sairre MI; Scott AL; Honorio KM
    Curr Top Med Chem; 2020; 20(3):209-226. PubMed ID: 31878857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery, synthesis and in combo studies of Schiff's bases as promising dipeptidyl peptidase-IV inhibitors.
    Abu Khalaf R; Awad M; Al-Essa L; Mefleh S; Sabbah D; Al-Shalabi E; Shabeeb I
    Mol Divers; 2022 Apr; 26(2):1213-1225. PubMed ID: 34553298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes.
    Kushwaha RN; Srivastava R; Mishra A; Rawat AK; Srivastava AK; Haq W; Katti SB
    Chem Biol Drug Des; 2015 Apr; 85(4):439-46. PubMed ID: 25216392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.